Organigram Processing

Moncton, NB, CanadaFounded 2013

Share:X / Twitter LinkedIn Suggest a correction

About Organigram Processing

Organigram's processing division manufactures cannabis derivatives including vapes, edibles, and concentrates, leveraging BAT's strategic investment for next-generation product innovation.

Key Facts

1British American Tobacco invested CAD $221 million for a 19.9% stake and a product development partnership
2Achieved leading market share in Canadian edibles and vape categories with brands like SHRED

Latest News

OGI Stock Gains Momentum as Organigram Earnings Draw Investor Attention

yesterday

Organigram Holdings captures market focus ahead of quarterly results, with cannabis investors watching for profitability signals in challenging sector conditions.

Organigram Posts Q2 Loss as Canadian Cannabis Market Pressures Mount

4d ago

OGI reports quarterly deficit while navigating ongoing headwinds in Canada's oversupplied recreational market

Organigram Q2 Revenue Falls Despite Raised Full-Year Guidance

6d ago

Canadian cannabis producer posts quarterly revenue decline but lifts FY outlook, creating mixed signals for investors in volatile market conditions.

Organigram Misses Revenue by 16% as Vape Sales Crater in Q2

6d ago

OGI reports $43.6M revenue vs $52M consensus as vape weakness and production issues hammer margins, sending adjusted EBITDA down 82% to $900K.

Organigram Holdings Plummets 14.2% as Cannabis Stock Faces Pressure

7d ago

OGI shares tumbled to $1.15 on heavy volume of 1.05M shares, highlighting ongoing volatility in the Canadian cannabis sector.

View all OGI news

Frequently Asked Questions

What is Organigram's relationship with BAT?

British American Tobacco invested in Organigram and established a Centre of Excellence collaboration to develop next-generation cannabis delivery and extraction technologies.